FLR Investors Have Opportunity to Lead Fluor Corporation Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstFluor Corporation (“Fluor” or “the Company”) (NYSE: FLR) forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased the Company's […]

Diamyd Medical’s pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026

The independent Data Safety Monitoring Board (DSMB) has completed its sixth scheduled safety review of Diamyd Medical's registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy Diamyd®. The review identified no safety concerns and resulted in a recommendation to continue the trial as planned. DIAGNODE-3 is conducted under Fast Track and Orphan Drug Designations

China-Singapore Tianjin Eco-City Becomes First Chinese City to Clinch Global Top Honor for Human Settlement Environment

TIANJIN, China, Nov. 14, 2025 (GLOBE NEWSWIRE) — The 20th Annual Session of Global Forum on Human Settlements (GFHS) & New Sustainable Cities and Human Settlements Awards Ceremony 2025 concluded in Geneva, Switzerland, on November 5. In a groundbreaking achievement for China's urban development, China-Singapore Tianjin Eco-City was honored as a global green and smart

China-Singapore Tianjin Eco-City Becomes First Chinese City to Clinch Global Top Honor for Human Settlement Environment

China-Singapore Tianjin Eco-City Becomes First Chinese City to Clinch Global Top Honor for Human Settlement Environment GlobeNewswire November 14, 2025 TIANJIN, China, Nov. 14, 2025 (GLOBE NEWSWIRE) — The 20th Annual Session of Global Forum on Human Settlements (GFHS) & New Sustainable Cities and Human Settlements Awards Ceremony 2025 concluded in Geneva, Switzerland, on November

2025 Guangxi Cultural and Tourism Development Conference To Be Held in Baise – A Borderland Secret Where Landscapes and Humanities Intertwine

BAISE, China, Nov. 14, 2025 (GLOBE NEWSWIRE) — The 2025 Guangxi Cultural and Tourism Development Conference will settle in Baise at the end of November. Held by the People's Government of Baise City, this grand cultural and tourism event is a sincere invitation from Baise to the world – earnestly hoping that Chinese and foreign

2025 Guangxi Cultural and Tourism Development Conference To Be Held in Baise – A Borderland Secret Where Landscapes and Humanities Intertwine

2025 Guangxi Cultural and Tourism Development Conference To Be Held in Baise – A Borderland Secret Where Landscapes and Humanities Intertwine GlobeNewswire November 14, 2025 BAISE, China, Nov. 14, 2025 (GLOBE NEWSWIRE) — The 2025 Guangxi Cultural and Tourism Development Conference will settle in Baise at the end of November. Held by the People's Government

Valeura Energy Inc. Announces Third Quarter 2025 Results

CALGARY, AB / ACCESS Newswire / November 14, 2025 / Valeura Energy Inc. (TSX:VLE)(OTCQX:VLERF) ("Valeura" or the "Company") reports its unaudited financial and operating results for the three and nine month periods ended September 30, 2025. Q3 Highlights Oil production of 23.0 mbbls/d(1) and oil sales of 2.2 million bbls; Average realised price of US$72.1/bbl,

Bioxodes presents BIOX-101 clinical data showing breakthrough potential for stroke in webcast with Prof Dr Robin Lemmens

Prof Lemmens underscores large unmet medical need in intracerebral hemorrhage “Very encouraging” data from Phase 2a trial with lead asset BIOX-101 Bioxodes is preparing for a possibly registrational Phase 2b trial, could bring BIOX-101 to market by late 2030 Gosselies, Belgium, 14 November 2025 (08:30 am CET) – Bioxodes SA, a clinical stage biopharmaceutical company

Bioxodes presents BIOX-101 clinical data showing breakthrough potential for stroke in webcast with Prof Dr Robin Lemmens

Bioxodes presents BIOX-101 clinical data showing breakthrough potential for stroke in webcast with Prof Dr Robin Lemmens GlobeNewswire November 14, 2025 Prof Lemmens underscores large unmet medical need in intracerebral hemorrhage “Very encouraging” data from Phase 2a trial with lead asset BIOX-101 Bioxodes is preparing for a possibly registrational Phase 2b trial, could bring BIOX-101

PRESS RELEASE: CMB.TECH announces Q3 2025 results on 26/11/2025

(NYSE:CMBT),(Brussels:CMBT),(Oslo Bors:CMBTO), Antwerp, Nov. 14, 2025 (GLOBE NEWSWIRE) — CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its third quarter 2025 earnings prior to market opening on Wednesday 26 November 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results

Scroll to Top